

Improving home dialysis

Weakid is a new portable peritoneal dialysis device that provides important benefits for renal patients compared with current techniques and reduces clinical workload.



- Continuously recirculates and regenerates the dialysate, removes toxins by adsorption, achieves greater blood purification (1.5-2x) than conventional treatment
- ✓ Does not require very high glucose concentrations, better preservation of the peritoneal membrane
- Less connections, lower peritonitis risk
- ✓ Remote surveillance via webportal

WEAKID

Innovative device for home-based effective peritoneal dialysis

What makes it different?



Continuous circulation & regeneration of dialysate by means of sorbents improves solute transfer across the peritoneal membrane and maintains high a concentration gradient throughout the treatment, increasing clearance




The improved clearance and low glucose eliminate current load drawbacks ∙of peritoneal dialysis



Remotely monitors dialysis parameters and diminishes the care burden



Easy to use and small size




Weakid in progress



Preclinical proof of concept already completed



First-in-human study planned in 2023



Usability test carried out in The Netherlands, Italy and Spain Crossover feasibility study to investigate the efficacy and safety over a longer period







We care about your patient

CORDIAL is a three year European project, in which two clinical studies with PD patients will be performed in order to validate the clinical safety and performance of the Weakid device.

Together with patients and clinical personnel, we will explore and evaluate how to make the system available to patients.



CORDIAL is a cooperation of nephrology departments from three European hospitals: UMC Utrecht (NL), UNIMORE (IT) and SERMAS (ES); and two companies: Nanodialysis (NL) and PPi Healthcare Consulting (UK).











